Latest News

PRESS RELEASE – Oslo, Norway, 16 October, 2020: Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study. It demonstrates that flexible Blue Light Cystoscopy helped resolve a substantial amount of cases by complete removal on-site or direct referral to intravesical treatment, providing increased efficacy to manage non-muscle-invasive bladder cancer (NMIBC) in the office setting.

Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira^® device in Europe until 2034.

Oslo, Norway, 1 October 2020: Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix^® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition and launch of European Hexvix operations creates a robust platform for accelerated growth and expansion for Photocure.

Oslo, Norway, 15 September 2020 - The board of directors in Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Oslo, Norway, 3 September 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 31 August 2020 regarding a share capital increase following the exercise of employee share options.

Oslo, Norway, 31 August 2020.

Participants in Photocure ASA's ("Photocure") share option program have on 31 August 2020 exercised a total of 17,366 options, distributed as follows:

Photocure's CEO Dan Schneider and CFO Erik Dahl will continue their dialogue with stakeholders at a live Q&A session on Wednesday, August 26, 2020, organized by Xtrainvestor on their facebook channel.

Oslo, Norway, 18 August 2020: Photocure ASA (OSE:PHO) reported Hexvix^®/Cysview^® revenues of 53.5 million in the second quarter of 2020 (Q2 2019: NOK 52.1), corresponding to growth of three per cent, despite a significant Covid-19 impact in the beginning of the quarter in the U.S. market before a strong recovery towards the end of the period. The company has entered into an agreement with Ipsen Pharma SAS (Ipsen) for the return of Hexvix sales, marketing and distribution rights from the fourth quarter of 2020 and sees significant growth opportunities in Europe. The agreement is expected to be EBITDA accretive from full-year 2021 and beyond.

Oslo, Norway, 13 August 2020: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2020 financial results on Tuesday 18 August 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

Oslo, Norway, 13 August 2020: Photocure ASA (OSE: PHO), today announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix^® in Chile.

Shanghai China, July 8, 2020 – Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for the treatment of genitourinary tumors and related diseases, announced today it has received Clinical Trial Approval (CTA) from China’s National Medical Products Administration (NMPA) for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product, APL-1702 (Cevira^®), which is being developed for the non-surgical treatment of high-grade cervical dysplasia (HSIL).

Oslo, Norway, 1 July 2020: Photocure ASA (OSE:PHO), today announced the appointment of Susanne Strauss as Vice President and General Manager of Europe, effective 1 July 2020.

FINANCIAL YEAR 2020

18.08.2020 - Half-yearly Report

12.11.2020 - Quarterly Report - Q3

Oslo, Norway, 26 June 2020: Reference is made to the previous stock exchange notices where Photocure ASA ("Photocure" or the "Company") announced the allocation of 2,500,000 shares at a subscription price of NOK 76 per share, raising gross proceeds of approx. NOK 190,000,000 in a private placement (the "Private Placement"). The shares will be listed on the Oslo Stock Exchange and are tradeable from today, 26 June 2020.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Oslo, Norway, 11 June 2020: Reference is made to the OSE notification 27 April 2020 from Photocure ASA (Photocure, PHO: OSE) regarding the return of Hexvix^® sales, marketing and distribution rights in Europe and other markets currently controlled by Ipsen Pharma SAS (Ipsen). Photocure and Ipsen have today entered into a final agreement.

Oslo, Norway, 10 June 2020: Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET).

Oslo, Norway, 10 June 2020: Photocure ASA (OSE:PHO) today announces the company’s first sustainability report, which will be presented at the Annual General Meeting (AGM) at 17:00 CET. The AGM will be live streamed and Dan Schneider, President & Chief Executive Officer, will provide a general company update.